Etoricoxib-induced fixed drug eruption: Report of seven cases.
Contact Dermatitis
; 84(3): 192-195, 2021 Mar.
Article
en En
| MEDLINE
| ID: mdl-32666601
ABSTRACT
BACKGROUND:
Fixed drug eruption (FDE) is a characteristic form of intraepidermal CD8+ T cell-mediated drug reaction, with repeated appearance of isolated or multiple skin lesions in the same location after receiving the offending drug. Non-steroidal anti-inflammatory drugs (NSAID) are the most common cause. Selective inhibitors of inducible cyclooxygenase 2 (COX-2) provoke a lesser degree of allergic or idiosyncratic adverse reactions than conventional NSAID, but they can cause skin reactions of variable severity.OBJECTIVE:
Etoricoxib has been related to a variety of unusual skin reactions, including several reports of FDE.METHODS:
We perfomed epicutaneous test to diagnose patients with suspected etoricoxib fixe drug rash due to clinical features and reproducibility on at least two occasions.RESULTS:
We present seven new cases of etoricoxib-induced fixed drug eruption, with a diagnosis based on clinical presentation. This diagnosis was confirmed by an etoricoxib-positive lesional patch test in six cases and by a positive low-dose oral challenge in the other one. Two patients showed negative patch tests with celecoxib (10% in pet.) on the residual lesions, and oral tolerance was confirmed in one.CONCLUSION:
To our knowledge, this is the largest series on FDE induced by etoricoxib reported to date.Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Antiinflamatorios no Esteroideos
/
Dermatitis Alérgica por Contacto
/
Erupciones por Medicamentos
/
Inhibidores de la Ciclooxigenasa 2
/
Etoricoxib
Tipo de estudio:
Diagnostic_studies
Límite:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Contact Dermatitis
Año:
2021
Tipo del documento:
Article
País de afiliación:
España